NCT07689006Completed
Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
Analysis of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Receiving Pomalidomide-Containing and Non-Pomalidomide-Containing Regimens in the Real World: A OneOncology United States Database Study
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
This retrospective observational study will use data from the OneOncology United States database to evaluate clinical outcomes in adults with relapsed/refractory multiple myeloma who received pomalidomide-containing or non-pomalidomide-containing treatment as second-line or third-line therapy after prior exposure to lenalidomide and a proteasome inhibitor.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 341 (actual)
- First submitted
- 30 Jun 2026
- Start date
- 23 Dec 2024
- Primary completion date
- 28 Mar 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Multiple myeloma
- NCT number
- NCT07689006
What you commit to
- Study type: Observational
- Participants enrolled: 341
- From 23 Dec 2024 to the primary completion date, 28 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received chimeric antigen receptor T-cell therapy or bispecific antibody therapy before index date or as the index line
Other illness
- Have other primary cancer diagnoses within 1 year pre-index
- Excluded ICD-10 diagnosis codes: C00.xx-C76.xx, C7A, C80.xx-C88.xx, C91.xx-C96.xx, D00.xx-D09.xx, D37.xx-D47.1x, D47.3x-D49.xx
- Excluded ICD-9 diagnosis codes: 149.x through 239.x
- ICD codes 209.4, 209.5, 209.6, 209.7, D47.Z1, D47.Z2, and D3A will not be excluded
Other
- Have \<6 months of follow-up from the index date; participants who died will be included even with \<6 months follow-up, but participants who died within 1 month after the index date will be excluded
- Have \<6 months pre-index enrollment
- Have ever enrolled in a clinical trial
Who the study is looking for
- Have a diagnosis of multiple myeloma (ICD-9: 203.00; ICD-10: C90.0x, C90)
- Are ≥18 years of age at the index date
- Have received a lenalidomide-containing regimen and received a proteasome inhibitor; exposures do not need to occur within the same line of therapy
- Have received ≥1 subsequent lines of therapy after lenalidomide and proteasome inhibitor exposure
- Have received one of the following treatment regimens as the subsequent line (index line) after lenalidomide and proteasome inhibitor exposure:
- Pomalidomide-containing regimens:
- Daratumumab, pomalidomide, and dexamethasone (DPd)
- Carfilzomib, pomalidomide, and dexamethasone (KPd)
- Non-pomalidomide-containing regimens:
- Daratumumab, lenalidomide, and dexamethasone (DRd; lenalidomide-refractory participants only)
- Daratumumab, bortezomib, and dexamethasone (DVd)
- Daratumumab, carfilzomib, and dexamethasone (DKd)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| OneOncology Network Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.